Galapagos NV : Galapagos increases share capital through warrant exercises
Mechelen, Belgium; 8April2013 - Galapagos NV (Euronext: GLPG) announced
today a capital increase arising from employee warrant exercises.
Since its inception in 1999, Galapagos has used warrant plans to incentivize
personnel and management and have them share in the success of the company.
Following warrant exercises during the exercise period from 9March2013
through 29March2013, Galapagos issued 197,581 new ordinary shares on
5April2013 for a total capital increase (including issuance premium) of
CEO Onno van de Stolpe exercised 50,000 warrants, granted in 2008 and which
were due to expire on 25 June 2013. Of these, 20,000 were exercised through a
cashless exercise facility to finance the cash exercise of 30,000 warrants.
Onno van de Stolpe's shareholding in Galapagos thereby increased by 30,000
shares to a total of 355,448 shares, or 1.32% of the outstanding Galapagos
To date, Galapagos' total share capital amounts to €145,884,501.48; the total
number of securities conferring voting rights is 26,968,328, which is also the
total number of voting rights (the "denominator"), and all securities
conferring voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued securities
conferring voting rights is 3,123,368, which equals the total number of voting
rights that may result from the exercise of these warrants. Galapagos does
not have any convertible bonds or shares without voting rights outstanding.
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline of four clinical, six pre-clinical, and
30 discovery small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about to
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778,
in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin
receptor antagonist currently in a Phase 1b patient study in metastasis.
GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for the
treatment of IBD; this program will start a Proof of Concept Phase 2 study in
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
Galapagos increases share capital through warrant exercises
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.